Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy

Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy

Oncolytic viruses (OVs) are being developed as a type of immunotherapy and have demonstrated durable tumor responses and clinical efficacy. One such OV, Coxsackievirus A21 (CVA21), exhibited therapeutic efficacy in early phase clinical trials, demonstrating the ability to infect and kill cancer cell...

Full description

Bibliographic Details
Main Authors: William J. Burnett, David M. Burnett, Gennie Parkman, Andrew Ramstead, Nico Contreras, William Gravley, Sheri L. Holmen, Matthew A. Williams, Matthew W. VanBrocklin
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
oncolytic virus
coxsackievirus
CVA21
virotherapy
picornavirus
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/13/17/4462

Similar Items

Similar Items